Porcine contagious actinobacillus pleuropneumoniae OMVs composition as well as preparation method and application thereof
Through hollow fiber concentration system and PEG concentration technology, the problems of difficulty in extracting outer membrane vesicles and high vaccine preparation cost in the prior art are solved, and efficient preparation and significant preventive effects of pig infectious pleuropneumonia vaccine are achieved.
Patent Information
- Application Number
- CN202411097146.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-12
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-08-12
AI Technical Summary
Most of the existing infectious pleuropneumonia vaccines are inactivated bacteria vaccines. The preparation process is cumbersome, the cost is high, and the immune effect is poor. The existing outer membrane vesicle extraction technology is difficult to operate and costly, so it cannot be applied to industrial production. .
The sample is concentrated by using a hollow fiber concentration system, combined with PEG concentration instead of ultracentrifugation, and prepared the OMVs composition of pig infectious Actinobacter pleuropneumoniae, used to prepare bivalent inactivated OMV vaccines, reduce the content of inactivated bacteria and increase the vaccine. Preventive effect.
The large-scale extraction of outer membrane vesicles has been achieved, reducing the difficulty and cost of operation, making the industrial production of pig infectious pleuropneumonia vaccine possible, and significantly improving the prevention effect of the vaccine.
Smart Images

Figure CN118909860A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of vaccine preparation, and more specifically to a porcine contagious Actinobacillus pleuropneumoniae OMVs composition and a preparation method and application thereof. Background Art
[0002] Porcine contagious pleuropneumonia is a highly contagious and fatal respiratory disease caused by Actinobacillus pleuropneumoniae (Apn), characterized by acute hemorrhage and chronic fibrinous necrotizing pleurisy lesions. This disease is susceptible to all kinds of pigs. In newly introduced pigs, it often breaks out acutely, with the morbidity and mortality rates often exceeding 20%, and the mortality rate of the most acute type can be as high as 80% to 100%. It often takes a chronic course in the herd, with the affected pigs showing chronic emaciation, or acute death caused by secondary other diseases. Asymptomatic pigs or recovered pigs can carry bacteria for a long time and become a stable source of infection. Porcine contagious pleuropneumonia is widely distributed. Since Pattison et al. first reported porcine contagious pleuropneumonia in 1957, the disease has been found to be prevalent in countries around the world. Since the disease is transmitted through air and contact, the more intensive the pig farming is, the more serious the disease is.
[0003] Outer membrane vesicles (OMVs) are products secreted from the surface of Gram-negative bacteria. They are formed by the outer membrane of bacteria budding under certain mechanisms and forming a vesicle-like structure on the surface of bacteria. This structure includes the outer membrane and periplasmic components. Most outer membrane vesicles are spherical, with a diameter of approximately 20–250 nm. In 1959, De et al. first discovered that the culture medium of Vibrio cholerae after filtering out bacteria could induce an immune response to Vibrio cholerae in rabbits. Chatterje et al., when studying the ultrastructure of Vibrio cholerae in the logarithmic growth period, found that there were vesicles formed by budding of the cell wall of Gram-negative bacteria in the sterile filtrate of the liquid culture medium, and the content of particulate matter was high near the site where the outer membrane was prone to vesicle budding, and these particles could enter the budding vesicles with the cytoplasm. The production of OMVs represents that bacteria have a unique mechanism to release large amounts of complex protein components and phospholipids to the external environment. Later studies found that almost all Gram-negative bacteria can produce OMVs. In addition to outer membrane proteins, their chemical structure also contains some other membrane components, so people call this membrane-structured vesicle an outer membrane vesicle. The outer membrane components contained in OMVs can stimulate the body to produce adaptive immune memory, the LPS contained can be used as a self-adjuvant, and as a non-replicating vaccine, it has a certain safety. Therefore, these factors make OMVs a popular choice for the development of non-replicating and highly effective vaccines.
[0004] At present, outer membrane vesicles are mostly extracted by ultracentrifuging twice using an ultracentrifuge. However, the ultracentrifuge can only process a limited amount of samples, is difficult to operate, is costly, time-consuming and labor-intensive, and cannot extract a large amount of outer membrane vesicles, making it unsuitable for industrial production. The present invention overcomes this defect. The present invention uses a hollow fiber concentration system to concentrate the sample, which can achieve a large amount of extraction of outer membrane vesicles. At the same time, PEG concentration is used instead of two ultracentrifugations, which reduces both the cost and the difficulty of operation, making it possible to extract a large amount of outer membrane vesicles and industrialize them.
[0005] At present, most of the vaccines for porcine infectious pleuropneumonia are inactivated bacteria vaccines, but the strain preparation process is cumbersome, the cost is high, and the immune effect is poor. OMVs have the characteristics of mediating the transfer of DNA fragments, autolytic enzymes, cytotoxins, virulence factors and various biological molecules. The composition of OMVs makes them an important factor in activating the host's innate and acquired immune response pathways. In addition to the powerful immunomodulatory molecule LPS, the vesicles also contain OM porins and other important innate immune activation ligands. The immunogenicity of OMVs can lead to protective mucosal and systemic bactericidal antibody responses and has been used in vaccine development. All current experimental evidence shows that the innate immune response to OMVs is the result of the combined action of bacteria-associated molecular patterns (PAMPs) and the recognition of LPS. The lipoproteins and OM proteins in the vesicles are bioactive molecules that can activate immune cells and induce leukocyte migration.
[0006] Therefore, how to apply outer membrane vesicles to porcine contagious pleuropneumonia vaccines and provide a vaccine that has a significant effect in preventing porcine contagious pleuropneumonia while reducing the content of inactivated bacteria is a technical problem that technical personnel in this field urgently need to solve. Summary of the invention
[0007] In view of this, the present invention provides a porcine Actinobacillus pleuropneumoniae OMVs composition, a preparation method and an application thereof.
[0008] In order to achieve the above object, the present invention adopts the following technical solution:
[0009] A porcine contagious Actinobacillus pleuropneumoniae OMVs composition, the composition is composed of OMVs secreted by porcine contagious Actinobacillus pleuropneumoniae type 1 GZ strain and OMVs secreted by Actinobacillus pleuropneumoniae type 7 ZQ strain, the OMVs are vesicle-like bodies with a double-layer membrane structure, and carry bacterial outer membrane and periplasmic components.
[0010] Another object of the present invention is to provide: a method for preparing the above-mentioned porcine contagious Actinobacillus pleuropneumoniae OMVs composition, comprising the following steps:
[0011] (1) fermenting and culturing porcine contagious pleuropneumoniae Actinobacillus 1 type GZ strain and type 7 ZQ strain for 8-10 hours respectively to prepare type 1 GZ strain fermentation liquid and type 7 ZQ strain fermentation liquid;
[0012] (2) centrifuging the two fermentation broths, taking the supernatant, and concentrating the supernatant through a hollow fiber system to prepare a type 1 GZ strain supernatant concentrate and a type 7 ZQ strain supernatant concentrate;
[0013] (3) The two supernatant concentrates were respectively concentrated by adding PEG at an amount of 6-14%, allowed to stand, and centrifuged. The precipitates were respectively resuspended in PBS and filtered to prepare type 1 GZ strain OMVs and type 7 ZQ strain OMVs, which were mixed to prepare a porcine contagious Actinobacillus pleuropneumoniae OMVs composition.
[0014] Preferably, the fermentation culture conditions in step (1) are as follows: fermentation temperature 37° C., stirring speed 100-200 rpm, pH 7.2-7.4, fermentation tank pressure 0.03-0.05 Pa, and fermentation time 8-10 h.
[0015] Preferably, the culture medium for the fermentation culture in step (1) is a TSB culture medium containing NAD and newborn calf serum, wherein the final concentration of NAD in the culture medium is 0.01%, and the final concentration of newborn calf serum is 2%.
[0016] Preferably, the centrifugal separation process in step (2) is as follows: 2-8°C, 8000rpm, centrifugation for 15min; the concentration is concentrated using a 300KDa hollow fiber system.
[0017] Preferably, the amount of PEG added in step (3) is 6-14% of the total weight of the supernatant concentrate, stirring is performed at 2-8°C for 4 hours, and the standing time is 18-24 hours; the centrifugal separation process is as follows: 12000rpm, 4°C, centrifugation for 30min; the filtration is performed using a 0.22μm filter membrane.
[0018] Another object of the present invention is to provide: use of the above OMVs composition or the OMVs composition prepared by the above method in the preparation of porcine contagious pleuropneumonia vaccine or vaccine adjuvant.
[0019] Another object of the present invention is to provide: a bivalent inactivated OMV vaccine for porcine contagious pleuropneumoniae, wherein the bivalent inactivated OMV vaccine comprises the above-mentioned porcine contagious Actinobacillus pleuropneumoniae OMVs composition.
[0020] Preferably, the bivalent inactivated OMV vaccine further comprises inactivated strains of porcine Actinobacillus pleuropneumoniae type 1 GZ strain and type 7 ZQ strain.
[0021] Another object of the present invention is to provide: a method for preparing a bivalent inactivated OMV vaccine for porcine contagious pleuropneumonia, comprising weighing each raw material according to the following weight parts and preparing the vaccine:
[0022] (1) Preparation of oil phase: Take 94 parts of white oil for injection, first add 6 parts of Siben-80, then add 2 parts of aluminum stearate while stirring, heat and stir until transparent, sterilize at high temperature and high pressure, and prepare the oil phase for use;
[0023] (2) Preparation of aqueous phase: According to the test results of viable bacterial count and BCA content of outer membrane vesicles, as required, the inactivated bacterial liquid of porcine Actinobacillus pleuropneumoniae type 1 GZ strain, the inactivated bacterial liquid of type 7 ZQ strain and the porcine Actinobacillus pleuropneumoniae OMVs composition are mixed in different proportions to prepare a mixed bacterial liquid containing outer membrane vesicles. 96 parts of the mixed bacterial liquid and 4 parts of sterilized Tween-80 are taken and mixed thoroughly to prepare an aqueous phase for later use;
[0024] (3) Emulsification: Take 2 portions of the oil phase and stir at a low speed while slowly adding 1 portion of the water phase. Stir at 4000 rpm for 30 min to emulsify into an oil emulsion. Before stopping stirring, add 1% thimerosal solution so that its final concentration in the vaccine does not exceed 0.01%. The porcine contagious pleuropneumonia bivalent inactivated OMV vaccine is prepared.
[0025] Preferably, the concentrations of the porcine Actinobacillus pleuropneumoniae type 1 GZ strain bacterial solution and type 7 ZQ strain inactivated bacterial solution in step (2) are both ≥ 3.2×10 9 CFU / mL, the two bacterial liquids were mixed in equal amounts, and the contents of both OMVs in the composition were ≥78.125 μg / mL.
[0026] Preferably, the concentration of outer membrane vesicles of Actinobacillus pleuropneumoniae type 1 GZ strain and type 7 ZQ strain in the bivalent inactivated OMV vaccine is 25 μg / ml.
[0027] It can be seen from the above technical solution that compared with the prior art, the present invention has the following beneficial effects:
[0028] (1) Animal experiments have shown that the bivalent inactivated OMV vaccine of the present invention has a significant effect in preventing porcine contagious pleuropneumonia;
[0029] (2) The prepared bivalent inactivated OMV vaccine for porcine contagious pleuropneumonia has a significant effect of preventing porcine contagious pleuropneumonia disease while reducing the inactivated bacterial content of Actinobacillus pleuropneumoniae type 1 GZ strain and type 7 ZQ strain;
[0030] (3) The present invention uses a hollow fiber concentration system to concentrate the sample, which can achieve large-scale extraction of outer membrane vesicles. At the same time, PEG concentration is used instead of two ultracentrifugations, which reduces both the cost and the difficulty of operation, making large-scale extraction and industrialization of outer membrane vesicles possible. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.
[0032] Figure 1 Figure 1 shows the preparation process of Actinobacillus pleuropneumoniae OMVs;
[0033] Figure 2 The attached figures are: transmission electron microscopic images of outer membrane vesicles of GZ strain and ZQ strain;
[0034] Figure 3 The attached figure is: protein concentration-absorbance standard curve;
[0035] Figure 4 The attached figure is: OMVs protein electrophoresis result diagram;
[0036] Figure 5 The attached figure is: the result of the outer membrane vesicle size detection of the GZ strain;
[0037] Figure 6 The attached figure shows the results of the outer membrane vesicle size detection of the ZQ strain. DETAILED DESCRIPTION
[0038] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0039] Example 1
[0040] Activation and expansion of strains
[0041] (1) Strain selection and activation: Take freeze-dried porcine contagious Actinobacillus pleuropneumoniae serotype 1 GZ strain (deposited in the General Microbiology Center of China National Microbiological Culture Collection Administration, with a deposit number of CGMCC NO.45994, a deposit date of June 24, 2024, and a taxonomic name: porcine contagious Actinobacillus pleuropneumoniae serotype 1) and type 7 ZQ strain (deposited in the General Microbiology Center of China National Microbiological Culture Collection Administration, with a deposit number of CGMCC NO.46086, a deposit date of June 24, 2024, and a taxonomic name: porcine contagious Actinobacillus pleuropneumoniae serotype 7).
[0042] After being dissolved in tryptone soy broth (TSB), the samples were inoculated into TSA slant medium containing 0.01% NAD and 2% newborn calf serum and placed in CO 2 The content was 5% to 10%, and the culture was cultured at 37°C for 24 hours. The culture was streaked onto TSA plates containing 0.01% NAD and 2% newborn calf serum, and cultured at 37°C for 16 to 18 hours. Then 5 to 10 typical colonies were selected and inoculated onto TSA slants containing 0.01% NAD and 2% newborn calf serum, respectively, and placed in CO 2 The content is 5% to 10%, and it is cultured at 37°C for 16 to 18 hours. After passing the purity inspection, it is used as the first-class seed.
[0043] (2) Expansion of strain culture: The primary seeds were inoculated into tryptone soy broth (TSB) medium containing 0.01% NAD and 2% newborn calf serum, and cultured at 37°C with shaking for 8 to 10 hours. After the samples were tested and passed the purity test, they were used as secondary seeds.
[0044] Example 2
[0045] Preparation of OMVs composition of Actinobacillus pleuropneumoniae
[0046] (1) The secondary seed solution of the strain prepared in Example 1 was taken and cultured separately in a biological fermentation tank. TSB medium was added at 60% to 70% of the total volume of the biological fermentation tank, and 0.02% of defoaming agent was added according to the amount of the medium for defoaming. When the temperature of the TSB medium dropped to about 37° C., NAD and newborn calf serum were added at 0.01% and 2% of the total amount of the medium, respectively. At the same time, the secondary seed solution of the GZ strain and the ZQ strain were inoculated at 3% to 5% of the total amount of the medium, respectively. The temperature was set to 37° C., the stirring speed was 100 to 200 rpm, the pH value was 7.2 to 7.4, the irrigation pressure was 0.03 to 0.05 Pa, and the culture was carried out for 8 to 10 hours;
[0047] (2) After separate fermentation and cultivation, the fermentation bacterial liquids of porcine contagious pleuropneumonia GZ strain and ZQ strain were obtained respectively, and the bacterial liquids were centrifuged at 8000 rpm, 4°C, for 15 min, and the supernatant was taken and the precipitate was discarded; the supernatant was concentrated by a 300 KDa hollow fiber system, and the OMVs were retained in the concentrated liquid, and finally the supernatant concentrated liquid was obtained;
[0048] (3) The supernatant concentrates of the two strains were added with PEG, stirred at 2-8°C for 4 hours, and then allowed to stand for 18-24 hours; centrifuged at 12000 rpm, 4°C, for 30 minutes, the supernatant was discarded, the precipitate was resuspended with PBS buffer, and filtered with a 0.22 μm filter membrane to obtain outer membrane vesicles of porcine contagious pleuropneumonia GZ strain and ZQ strain, respectively, and mixed to obtain an Actinobacillus pleuropneumoniae OMVs composition. OMVs are vesicle-like bodies with a double-layer membrane structure, which carry bacterial outer membrane and periplasmic components, including enzymes, virulence factors, bacterial-specific antigens and a variety of pathogen-related molecular patterns, and are stored at -80°C for future use. The preparation process is as follows: Figure 1 shown.
[0049] Example 3
[0050] Analysis of OMVs of Actinobacillus pleuropneumoniae
[0051] (1) TEM characterization: The uniformly dispersed GZ strain outer membrane vesicles and ZQ strain outer membrane vesicles prepared in Example 2 were diluted to 500-800 μg / ml, and 10 μL of the dilution solution was dripped on the copper mesh. After adsorption for half an hour, the mixture was blotted with filter paper. Subsequently, 10 μL of 1% phosphotungstic acid was dripped on the mixture and stained for 3-5 minutes, and then the mixture was blotted with filter paper. The size and morphology of OMVs derived from GZ strain and ZQ strain of Actinobacillus pleuropneumoniae were observed by TEM. TEM showed a complete shape and regular spherical structure, with a particle size of less than 200 nm. The transmission electron microscope image of the OMVs is shown in the following figure. Figure 2 shown.
[0052] (2) OMVs protein quantification: The BCA method was used to determine the protein concentration of OMVs. A protein concentration-absorbance standard curve was established using a protein standard according to the standard steps in the instruction manual (e.g. Figure 3 ), R 2 =0.9944>0.99, showing a good linear relationship; 25 μL of 10-fold diluted OMVs sample was added to two replica wells, and then 200 μL of BCA working solution was added, and the samples were placed at 37°C for 30 min, and the absorbance was measured at a wavelength of 562 nm.
[0053] Result analysis: After calculation, the protein concentrations of OMVs of GZ and ZQ strains were 10.452 mg / mL and 16.599 mg / mL, respectively. The yields were high and could be used for industrial production.
[0054] (3) OMVs protein types: Take 80 μL of GZ strain and ZQ strain OMVs solution diluted to 500-800 μg / ml, mix with 20 μL of 5× protein loading buffer and boil for 10 min. Take 10 μL and 20 μL of the boiled mixed sample and 5 μL of Mark for each type and load them on 12% SDS-PAGE, run electrophoresis at 80 V for 20 min, then at 100 V for 30 min, then stain with Coomassie Brilliant Blue and decolorize with decolorizing solution. The electrophoresis results are as follows: Figure 4 shown.
[0055] Result analysis: Figure 4 The protein SDS-PAGE electrophoresis of OMVs of Actinobacillus pleuropneumoniae GZ strain and ZQ strain showed that there were multiple protein bands, and the sizes of the protein bands were mainly between 25 KDa and 200 KDa.
[0056] (4) Particle size detection: Preheat the nanoparticle size and zeta potential instrument for 30 minutes, add 1 mL of LOMV sample to the sample cup, and the sample concentration should be no less than 25 μg / mL. Place the sample cup in the sample slot, select the "size" mode to enter the particle size measurement interface, and perform the test. The results are as follows: Figure 5 (type 1 GZ strain) and Figure 6 (Type 7 ZQ strain) as shown.
[0057] Result analysis: The average particle size of GZ strain was 82.62nm, and the average particle size of ZQ strain was 78.38nm.
[0058] Example 4
[0059] Preparation of the bivalent inactivated OMV vaccine for porcine contagious pleuropneumonia of the present invention
[0060] (1) Oil phase preparation
[0061] Take 94 parts of white oil for injection, first add 6 parts of Siben-80, then add 2 parts of aluminum stearate while stirring, heat and stir until transparent, sterilize at high temperature and high pressure, and prepare the oil phase for use.
[0062] (2) Preparation of aqueous phase
[0063] a: Preparation of Actinobacillus pleuropneumoniae liquid:
[0064] Actinobacillus pleuropneumoniae type 1 GZ strain and type 7 ZQ strain were cultured in fermenters separately until the stable phase, and bacterial liquids were obtained respectively;
[0065] After the culture of the bacterial solution is completed, samples are taken for purity test using tryptone soy agar (TSA) medium containing 0.01% NAD and 2% serum. At the same time, samples are taken for viable bacterial count. The number of viable bacteria in each bacterial solution should be ≥4.5×109 CFU / ml.
[0066] Slowly add formaldehyde solution at 0.3% of the total bacterial solution, mix thoroughly, and inactivate at 37°C for 24 hours, stirring 4 to 6 times during the process. After the bacterial solution passes the inactivation test, store it at 2 to 8°C for future use.
[0067] b: Preparation of the aqueous phase of the mixture of two bacterial suspensions and Actinobacillus pleuropneumoniae OMVs composition:
[0068] According to the results of live bacterial count and BCA content test of outer membrane vesicles, the two bacterial liquids were mixed with OMVs composition of Actinobacillus pleuropneumoniae (Note: OMV+1 / 2 whole bacterial cell vaccine was made into ≥1.6×10 9 CFU / ml, and then mixed in equal amounts, the content of the two OMVs in the composition was ≥78.125μg / ml; OMV+1 / 3 whole bacterial cell vaccine was made into two bacterial liquids ≥1.09×10 9 CFU / ml and then mixed in equal amounts, the content of the two OMVs in the composition is ≥78.125μg / ml) to prepare a mixed bacterial solution of outer membrane vesicles, take 96 parts of the mixed bacterial solution of outer membrane vesicles and 4 parts of sterilized Tween-80, mix them thoroughly, and prepare an aqueous phase for use.
[0069] (3) Emulsification
[0070] Take 2 portions of the oil phase and stir at a low speed while slowly adding 1 portion of the water phase, stirring at 4000 rpm for 30 minutes to emulsify into an oil emulsion, add 1% thimerosal solution before stopping stirring so that the final concentration does not exceed 0.01%, and the porcine contagious pleuropneumonia bivalent inactivated OMV vaccine is obtained.
[0071] The sterility test shall be carried out according to the appendix of the current "Chinese Veterinary Pharmacopoeia" and there should be no sterile growth.
[0072] Example 5
[0073] Preparation of bivalent inactivated vaccine for porcine contagious pleuropneumonia (type 1 GZ strain + type 7 ZQ strain) i.e. whole bacterial vaccine
[0074] (1) Oil phase preparation
[0075] Take 94 parts of white oil for injection, first add 6 parts of Siben-80, then add 2 parts of aluminum stearate while stirring, heat and stir until transparent, sterilize at high temperature and high pressure, and prepare the oil phase for use.
[0076] (2) Preparation of aqueous phase
[0077] a: Preparation of Actinobacillus pleuropneumoniae liquid:
[0078] Actinobacillus pleuropneumoniae type 1 GZ strain and type 7 ZQ strain were cultured in fermenters separately until the stable phase, and bacterial liquids were obtained respectively;
[0079] After the culture of the bacterial solution is completed, samples are taken for purity test using tryptone soy agar (TSA) medium containing 0.01% NAD and 2% serum. At the same time, samples are taken for viable bacterial count. The number of viable bacteria in each bacterial solution should be ≥4.5×10 9 CFU / ml.
[0080] Slowly add formaldehyde solution at 0.3% of the total bacterial solution, mix thoroughly, and inactivate at 37°C for 24 hours, stirring 4 to 6 times during the process. After the bacterial solution passes the inactivation test, store it at 2 to 8°C for future use.
[0081] b: Preparation of mixed aqueous phase of two Actinobacillus pleuropneumoniae:
[0082] According to the results of the live bacteria count test, the two bacterial solutions (the two bacterial solutions were made into no less than 3.2×10 9 CFU / ml and then mixed in equal amounts), 96 parts of the mixed bacterial solution and 4 parts of sterilized Tween-80 were taken and mixed thoroughly to prepare the aqueous phase for use.
[0083] (3) Emulsification
[0084] Take 2 portions of the oil phase and stir at a low speed while slowly adding 1 portion of the water phase, stirring at 4000 rpm for 30 minutes to emulsify into an oil emulsion, add 1% thimerosal solution before stopping stirring so that the final concentration does not exceed 0.01%, and the porcine contagious pleuropneumonia bivalent inactivated vaccine is prepared.
[0085] The sterility test shall be carried out according to the appendix of the current "Chinese Veterinary Pharmacopoeia" and there should be no sterile growth.
[0086] Example 6
[0087] Immunization challenge test of bivalent inactivated OMV vaccine against porcine contagious pleuropneumonia
[0088] (1) Grouping of immune challenge experiments
[0089] The test seedlings were prepared according to the contents listed in Table 1 and the method described in Example 4.
[0090] (2) Immunity
[0091] 60 healthy susceptible piglets (APP indirect hemagglutination titer ≤ 1:4) aged 5-6 weeks were selected and divided into 14 groups (as listed in Table 1), with 5 piglets in each group. Immunization was performed according to the groups in Table 1, and groups 13-14 were used as controls, with each piglet injected with the same dose of sterile saline. Note: The whole bacterial vaccine was prepared according to the method described in Example 5.
[0092] (3) Attack
[0093] After 28 days of immunization, each immunized group together with the control group was divided into experimental groups (see Table 1 for immunization and challenge grouping table) and injected intratracheally with 2.0 ml of a minimum pathogenic dose (toxin testing is required before challenge) of GZ strain or ZQ strain virulent bacterial liquid. The animals were observed for 14 days. The results of the challenge experiment are shown in Table 2.
[0094]
[0095]
[0096]
[0097]
[0098] Results analysis: From the results of the attack in Table 2, we can see that:
[0099] 1. The protection of OMV vaccine with OMV plus bacteria is higher than that of OMV vaccine alone;
[0100] 2. The protection rate of the vaccine with two kinds of bacterial OMVs was significantly higher than that without them;
[0101] 3. The protection rate of the bacterial vaccine with two kinds of bacterial OMVs was significantly improved compared with the corresponding vaccine groups with only 1 / 2 bacteria and 1 / 3 bacteria.
[0102] In summary, the bivalent inactivated vaccine against porcine contagious pleuropneumonia (type 1 GZ strain + type 7 ZQ strain) with the addition of OMVs of porcine contagious pleuropneumonia type 1 GZ strain and type 7 ZQ strain has a protective effect on animals and has the effect of significantly enhancing their immune efficacy. At the same time, it can still achieve a good immune effect while reducing the bacterial content, which reduces the cost and improves the quality of the vaccine. It can indeed be developed and applied as a new vaccine.
[0103] The various embodiments in the specification are described in a progressive manner, and each embodiment focuses on the differences from other embodiments, and the same and similar parts between the various embodiments can be referred to each other. The above description of the disclosed embodiments enables professionals and technicians in the field to implement or use the present invention. Various modifications to these embodiments will be obvious to professionals and technicians in the field, and the general principles defined herein can be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but will conform to the widest range consistent with the principles and novel features disclosed herein.
Claims
1. A porcine Actinobacillus pleuropneumoniae OMVs composition, characterized in that: The composition is composed of OMVs secreted by porcine contagious Actinobacillus pleuropneumoniae type 1 GZ strain and OMVs secreted by porcine contagious Actinobacillus pleuropneumoniae type 7 ZQ strain. The OMVs are vesicle-like bodies with a double-layer membrane structure, which carry bacterial outer membrane and periplasmic components.
2. A method for preparing the porcine Actinobacillus pleuropneumoniae OMVs composition according to claim 1, characterized in that: The steps include: (1) fermenting and culturing porcine contagious Actinobacillus pleuropneumoniae type 1 GZ strain and type 7 ZQ strain respectively to prepare type 1 GZ strain fermentation bacterial liquid and type 7 ZQ strain fermentation bacterial liquid; (2) centrifuging the two fermentation broths, taking the supernatant, and concentrating the supernatant through a hollow fiber system to prepare a type 1 GZ strain supernatant concentrate and a type 7 ZQ strain supernatant concentrate; (3) The two supernatant concentrates were respectively concentrated by adding PEG at an amount of 6-14%, allowed to stand, and centrifuged. The precipitates were respectively resuspended in PBS and filtered to prepare type 1 GZ strain OMVs and type 7 ZQ strain OMVs, which were mixed to prepare a porcine contagious Actinobacillus pleuropneumoniae OMVs composition.
3. The preparation method according to claim 2, characterized in that: The fermentation conditions of step (1) are as follows: fermentation temperature 37° C., stirring speed 100-200 rpm, pH 7.2-7.4, fermentation tank pressure 0.03-0.05 pa, and fermentation time 8-10 h; The culture medium for the fermentation culture in step (1) is a TSB culture medium containing NAD and newborn calf serum, wherein the final concentration of NAD in the culture medium is 0.01%, and the final concentration of newborn calf serum is 2%.
4. The preparation method according to claim 2, characterized in that: The centrifugal separation process in step (2) is as follows: 2-8°C, 8000rpm, centrifugation for 15min; the concentration is carried out using a 300KDa hollow fiber system; In step (3), the amount of PEG added is 6-14% of the total weight of the supernatant concentrate, and the mixture is stirred at 2-8°C for 4 hours; the standing time is 18-24 hours; the centrifugal separation process is as follows: 12000rpm, 4°C, centrifugation for 30min; and the filtration is performed using a 0.22μm filter membrane.
5. Use of the OMVs composition according to claim 1 or the OMVs composition prepared by the method according to claims 2-4 in the preparation of porcine contagious pleuropneumonia vaccine or vaccine adjuvant.
6. A bivalent inactivated OMV vaccine for porcine contagious pleuropneumonia, characterized in that: The bivalent inactivated OMV vaccine comprises the porcine contagious Actinobacillus pleuropneumoniae OMVs composition of claim 1.
7. The bivalent inactivated OMV vaccine for porcine contagious pleuropneumonia according to claim 6, characterized in that: Also included are inactivated strains of porcine contagious Actinobacillus pleuropneumoniae type 1 GZ strain and type 7 ZQ strain.
8. A method for preparing a bivalent inactivated OMV vaccine for porcine contagious pleuropneumonia, characterized in that: Weigh each raw material according to the following weight parts and prepare: (1) Preparation of oil phase: Take 94 parts of white oil for injection, first add 6 parts of Siben-80, then add 2 parts of aluminum stearate while stirring, heat and stir until transparent, sterilize at high temperature and high pressure, and prepare the oil phase for use; (2) Preparation of aqueous phase: According to the test results of viable bacterial count and BCA content of outer membrane vesicles, as required, the inactivated bacterial liquid of porcine Actinobacillus pleuropneumoniae type 1 GZ strain, the inactivated bacterial liquid of type 7 ZQ strain and the porcine Actinobacillus pleuropneumoniae OMVs composition are mixed in different proportions to prepare a mixed bacterial liquid containing outer membrane vesicles, and 96 parts of the mixed bacterial liquid and 4 parts of sterilized Tween-80 are taken and mixed thoroughly to prepare an aqueous phase for later use; (3) Emulsification: Take 2 portions of the oil phase and stir at a low speed while slowly adding 1 portion of the water phase. Stir at 4000 rpm for 30 min to emulsify into an oil emulsion. Before stopping stirring, add 1% thimerosal solution so that its final concentration in the vaccine does not exceed 0.01%. The porcine contagious pleuropneumonia bivalent inactivated OMV vaccine is obtained.
9. The preparation method according to claim 8, characterized in that: The concentrations of the porcine contagious pleuropneumoniae Actinobacillus 1 GZ strain bacterial solution and the porcine contagious pleuropneumoniae Actinobacillus 7 ZQ strain inactivated bacterial solution in step (2) are both ≥3.2×10 9 CFU / mL, the two bacterial liquids were mixed in equal amounts, and the contents of both OMVs in the composition were ≥78.125 μg / mL.
10. The preparation method according to claim 8, characterized in that: The concentrations of the outer membrane vesicles of Actinobacillus pleuropneumoniae type 1 GZ strain and type 7 ZQ strain in the porcine contagious pleuropneumonia bivalent inactivated OMV vaccine are both 25 μg / ml.
Citation Information
Patent Citations
Antigens for actinobacillus pleuropneumoniae and methods thereof
CA2510654A1
Preparation method of APP (Actinobacillus Pleuropneumoniae) OMVs (Outer Membrane Vesicles) and vaccine of APP OMVs
CN105420161A
Bacterial membrane preparations
CN113727722A
Preparation method and application of porcine contagious actinobacillus pleuropneumoniae type 1 GZ strain outer membrane vesicles
CN118879558A
Preparation method and application of porcine contagious actinobacillus pleuropneumoniae 7 type ZQ strain outer membrane vesicles
CN118895228A
